Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

dition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval, including with respect to TREANDA; manufacturing development and capabilities; market prospects for its products, including with respect to AMRIX; sales, adjusted net income and basic adjusted income per common share guidance for 2007 and 2008; and other statements regarding matters that are not historical facts, including the Company's position and expected performance in 2007 and 2008, the final resolution or outcome of the ongoing investigations by the U.S. Attorney's Office and the Office of the Connecticut Attorney General and the final amount of any settlement and/or fines related thereto, and the relative strength of the foundation for the Company's ongoing compliance efforts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermo
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... various reagents used in the life science ... the life science reagents market towards remarkable ... manufacturers and providers of life science reagents. ... Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global ...
(Date:7/11/2014)... EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is ... . The new Wyss Center for Bio- ... Geneva , has named as its director one ... Donoghue , founder of Brown University,s Institute for Brain ...
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... 10, 2014 Robert Harman, DVM, Founder and ... is proud to announce the relaunch of his highly informative ... new series called “ What are Stem Cells ?” ... and straightforward foundation in the basics of stem cell therapy ... the right type of treatment when considering regenerative medicine. , ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... , COLUMBUS, Ohio, Nov. 30 The ... the nation,s first minority business early-stage capital summits. The ... "Transforming the Landscape of Business in America: A Minority Business ... national minority business leaders and local minority entrepreneurs. , ...
... Minn., Nov. 30 Acuo Technologies, developers of high-performance ... today announced contracting with Allina Hospitals and Clinics for ... of image storage across the Allina network of hospitals, ... on the Acuo Technologies DICOM Services Grid(TM) Software. ...
... , ... 2 (GPP2), a key guidance document for the publication of ... British Medical Journal (BMJ). "The publication of GPP2 in BMJ ... guidance for industry sponsored research and the publication of study ...
Cached Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... New South Wales, Australia when NASA,s Aqua satellite passed ... July 11 (12:35 p.m. local time/11:35 p.m. EDT on ... Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spotted smoke (light brown) from various fires. Actively burning ... red. , The New South Wales, Australia Government website ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... , Today, Andrew Viterbi, Donald Bitzer and John Daugman ... Inventors Hall of Fame at the United States Patent ... and their accomplishments are in part a testimony to ... Viterbi, an electrical engineer and cofounder of wireless ...
... appearing in the Journal of Nutritional Biochemistry demonstrates that ... chronic high blood pressure (hypertension) by increasing the activity ... heart tissue. Grapes are a known natural source ... be responsible for the beneficial effects observed with grape ...
... that aimed to understand how the cancer drug everolimus ... trastuzumab has left researchers contemplating a puzzle. , The ... rates for some patients with early breast cancer when ... results suggest this benefit is achieved independently of the ...
Cached Biology News:New National Inventors Hall of Fame inductees received vital NSF support 2New National Inventors Hall of Fame inductees received vital NSF support 3New National Inventors Hall of Fame inductees received vital NSF support 4Study uncovers mechanism for how grapes reduce heart failure associated with hypertension 2Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer 2Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer 3
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids ... Purification immunoaffinity purified Quality ... RIPA lysates from HeLa cells. ...
...
Replacement Parts for Electrophoresis Apparatus...
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Biology Products: